Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q1 2026 Earnings Call Transcript May 7, 2026Definium Therapeutics, Inc. misses on earnings expectations.
Definium Therapeutics Inc. (DFTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 0 | $0 | 0% | |
| 2. | Quantinno Capital Hoon Kim | 0 | $0 | 0% | |
| 3. | OrbiMed Advisors Samuel Isaly | 0 | $0 | 0% | |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 0 | $0 | 0% | |
| 5. | Millennium Management Israel Englander | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.17 | 2,500 | $17,925.00 | 19,851 | 2024-12-05 | Filing | |
| $5.98 | 3,500 | $20,930.00 | 17,351 | 2024-08-23 | Filing | |
| $6.12 | 500 | $3,060.00 | 565,543 | 2024-08-20 | Filing | |
| $6.31 | 500 | $3,155.00 | 565,043 | 2024-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.47 | 8,018 | $148,092.46 | 413,317 | 2026-03-25 | Filing | |
| $18.47 | 10,702 | $197,665.94 | 271,079 | 2026-03-25 | Filing | |
| $18.47 | 24,431 | $451,240.57 | 752,454 | 2026-03-25 | Filing | |
| $13.15 | 5,600 | $73,622.64 | 425,025 | 2025-12-26 | Filing | |
| $13.15 | 25,791 | $339,071.70 | 778,477 | 2025-12-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,000 | $321,300 | 0% | |
| 2. | 1 | $1 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
9 Best Psychedelic Stocks to Buy in 2026
The AdvisorShares Psychedelics ETF, a fund that primarily invests in the psychedelic drugs sector, is up 31% over the past year. That almost doubles the S&P 500’s 16% gain over the same timeframe.
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript
Definium Therapeutics, Inc. (NASDAQ:DFTX) Q4 2025 Earnings Call Transcript February 26, 2026Definium Therapeutics, Inc. reports earnings inline with expectations.
Jefferies Assigns 65–75% Probability of Best-in-Class Efficacy for Definium Therapeutics, Inc.'s (DFTX) DT120 in Phase III
TheFly reported on January 30 that Jefferies initiated coverage of DFTX with a Buy rating and a $30 price target.
7 Most Promising Psychedelic Stocks According to Hedge Funds
The psychedelic industry is poised to have a significant "second wave," transforming from a speculative, counterculture-driven movement into a recognized cornerstone of the US healthcare system.
Hedge Fund Resource Center